Skip to main content
ZYDUSLIFE · Health Care · 2026-08-21

Zydus Lifesciences Ltd

5.2★ FairSolid +5.8Stage 2 · wk 12In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹1,120
+1.11% today
₹1,11,720 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Visit company website →
P/E (TTM)
21.7
Forward 23.3
Earnings Growth (YoY)
+8.7%
Revenue +16.2%
ROE
+18.3%
Profit margin +18.6%
Dividend Yield
0.09%
P/B 4.3
vs 52W High
-7.1%
₹860.6 lo₹1,205 hi
7.1% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 12
1w13w26w
Week 12 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
14.1%
200 DMA: ₹981.3 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.70x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 flat · +0.2% vs MA50 +2.4%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #49 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #36 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 20w
S2 42w
S4 28w
S2 18w
S4 16w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 20w → S3 7w → S2 42w → S3 8w → S4 28w → S1 6w → S2 18w → S3 6w → S4 16w → S1 6w → S2 11w current
Total tracked: 169 weeks across 11 stage runs.
1M
+0.6%
3M
+7.8%
6M
+23.0%
YTD
+23.8%
1Y
+13.3%
Scan Membership
Breakout Watch
Latest: 2026-06-03
2 appearances in last 60 days. First seen: 2025-07-18.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 12 · Vol x
2026-08-20S2
Wk 12 · Vol x
2026-08-19S2
Wk 11 · Vol x
2026-08-18S2
Wk 11 · Vol x
2026-08-17S2
Wk 11 · Vol x
2026-08-14S2
Wk 11 · Vol x
2026-08-13S2
Wk 11 · Vol x
2026-08-12S2
Wk 10 · Vol x
2026-08-11S2
Wk 10 · Vol x
2026-08-10S2
Wk 10 · Vol x
2026-08-07S2
Wk 10 · Vol x
2026-08-06S2
Wk 10 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,122.8
200 DMA
₹981.3
52W High
₹1,205
52W Low
₹860.6
5D Low
₹1,104.5
Resistance levels (recent highs)
20d High
₹1,205
60d High
₹1,205
120d High
₹1,205
250d High
₹1,205
Next resistance
+7.6%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.